Hillstream BioPharma CEO Randy Milby joins Natalie Stoberman from the Proactive studio to describe the company's emerging treatment for ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers.
Hillstream’s most advanced therapeutic candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to be efficacious in a clinical pilot study in Germany in devastating cancers, including triple negative breast cancer and epithelial carcinomas.